The long-term efficacy of heliotherapy in ameliorating disease severity and improving the quality of life in patients with atopic dermatitis.
Dermatology Life Quality Index
SCORing Atopic Dermatitis
atopic dermatitis
eczema
heliotherapy
quality of life
Journal
Postepy dermatologii i alergologii
ISSN: 1642-395X
Titre abrégé: Postepy Dermatol Alergol
Pays: Poland
ID NLM: 101168357
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
07
06
2022
accepted:
05
07
2022
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
ppublish
Résumé
Atopic dermatitis is one of the most common chronic inflammatory skin diseases adversely affecting the quality of life of both patients and their families. Heliotherapy, a treatment modality with high anti-inflammatory effects, is unjustifiably neglected in a country that has plenty of sunshine days throughout the year, but does not own the Cabinet for artificial phototherapy. To evaluate the power of individual heliotherapy in ameliorating disease severity and improving the quality of life, as well as to compare the results with those obtained from the studies evaluating group heliotherapies. We assessed disease severity and quality of life at three times: before commencing heliotherapy (Time 1), immediately after heliotherapy (Time 2), and 3 months after heliotherapy (Time 3). The tools we used are authorized scoring systems and questionnaires: SCORing Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI) and Severity of Pruritus Scale (SPS). A total of 24 patients were analysed in this observational study. Good clinical results were observed with a statistically significant decrease in SCORAD index by 40% and 31.1% at Time 2 and Time 3, respectively ( Our results revealed that 2-week heliotherapy has shown satisfying, long-lasting effects in clearing the skin changes, reducing and ameliorating pruritus intensity, as well as improving the quality of life.
Identifiants
pubmed: 36909908
doi: 10.5114/ada.2022.124681
pii: 50037
pmc: PMC9993203
doi:
Types de publication
Journal Article
Langues
eng
Pagination
159-164Informations de copyright
Copyright: © 2023 Termedia Sp. z o. o.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Actas Dermosifiliogr (Engl Ed). 2020 Apr;111(3):205-221
pubmed: 31964499
Nutr Today. 2015 May;50(3):117-128
pubmed: 27340299
Arch Dermatol Res. 2009 Mar;301(3):197-203
pubmed: 19142651
Allergy Asthma Proc. 2017 Jan 1;38(1):3-8
pubmed: 28052794
J Eur Acad Dermatol Venereol. 2018 Jan;32(1):23-38
pubmed: 28833648
Br J Dermatol. 2007 Oct;157(4):645-8
pubmed: 17714568
Allergol Immunopathol (Madr). 2008 Jul-Aug;36(4):205-11
pubmed: 18928687
Acta Derm Venereol. 2000 Jul-Aug;80(4):272-6
pubmed: 11028860
Prog Biophys Mol Biol. 2006 Sep;92(1):80-5
pubmed: 16600340
Acta Derm Venereol. 2015 May;95(5):579-82
pubmed: 25474161
Drugs Aging. 2020 Mar;37(3):149-160
pubmed: 32086792
Photodermatol Photoimmunol Photomed. 2016 Sep;32(5-6):254-261
pubmed: 27379840
Dermatitis. 2012 Mar-Apr;23(2):75-80
pubmed: 22653123
Am J Manag Care. 2017 Jun;23(8 Suppl):S115-S123
pubmed: 28978208
Br J Dermatol. 2017 Nov;177(5):1316-1321
pubmed: 28485036
Acta Med Port. 2019 Sep 2;32(9):606-613
pubmed: 31493365
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Allergy. 2018 Jun;73(6):1284-1293
pubmed: 29319189
Postepy Dermatol Alergol. 2020 Feb;37(1):66-72
pubmed: 32467687
Acta Derm Venereol. 2002;82(6):436-40
pubmed: 12575850
Front Med (Lausanne). 2018 Nov 30;5:333
pubmed: 30560129
Asia Pac Allergy. 2016 Oct;6(4):213-219
pubmed: 27803881
Dermatol Clin. 2017 Jul;35(3):283-289
pubmed: 28577797
Allergy. 2012 Jan;67(1):99-106
pubmed: 21951293
Coll Antropol. 2014 Dec;38(4):1249-53
pubmed: 25842770
J Invest Dermatol. 2005 Oct;125(4):840-6
pubmed: 16185286
Ann Dermatol Venereol. 2017 Dec;144 Suppl 5:VS23-VS28
pubmed: 29433634